Type 1 Diabetes Clinical Trial
— DiabeloopWP6-0Official title:
Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.
The main objective is to assess if the Diabeloop algorithm provides better glycemic control
than a "manual" usual algorithm of patients with type 1 diabetes treated by insulin pump
during meals, and during activity qualified "moderate" to "severe" by the patients.
The study will be conducted in 18 patients. The investigation centers are: CHSF (for
Diabeloop algorithm test during activity), CHU of Grenoble and CHU of Toulouse (for
Diabeloop algorithm test during meals.
Status | Completed |
Enrollment | 18 |
Est. completion date | July 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with type 1 diabetes treated by external insulin pump; - Patients with HbA1c <8.5%. - Patients aged 18 years or less; - Patient who signed consent; - Patient affiliated with Social Security. For Grenoble and Toulouse Centers (Prandial algorithm test : MEAL): - Patient is practicing functional insulin therapy is a fixed meal plan. For CHSF center (test of algorithm during activity): - Patient able to perform moderate or intense activity during 30 minutes. Exclusion Criteria: - Patients with type 2 diabetes - All serious diseases that could interfere with the study - Insulin resistance and obesity (BMI> 30 kg/m2 and / or insulin requirements> 2 U / kg / day) |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Sud Francilien | Evry | |
France | University Hospital of Grenoble | Grenoble | |
France | University Hospital of Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night. | Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC, in conditions identical meals for each trigger level (50 or 75%). Comparison of blood glucose 2h, 3h and 4h post-prandial and AUC, in conditions identical meals for each trigger level, in three configurations: quantitative, semi-quantitative and bolus omitted. Measuring AUC, during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night; Measure the time spent in hypoglycemia (<0.70 g / l) Measuring the number of carbohydrate ingested |
After the end of the tests | Yes |
Primary | Time spent in glucose reference intervals | After the end of the tests | Yes | |
Secondary | Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia) | To evaluate the efficacy and safety of prandial algorithm, informed carbohydrate intake by the patient either quantitatively or semi-quantitative, or not informed way. | After the end of the tests | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |